Stifel Maintains Buy on OptimizeRx, Maintains $13 Price Target
Portfolio Pulse from Benzinga Newsdesk
Stifel analyst David Grossman maintains a Buy rating on OptimizeRx (NASDAQ: OPRX) with a $13 price target.
May 15, 2024 | 11:51 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Stifel analyst David Grossman maintains a Buy rating on OptimizeRx with a $13 price target, indicating confidence in the company's future performance.
The Buy rating and maintained price target of $13 from a reputable analyst like David Grossman of Stifel suggests a positive outlook for OptimizeRx. This could lead to increased investor confidence and a potential short-term price increase.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100